Literature DB >> 17510408

Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes.

Danielle K Sandsmark1, Huabiao Zhang, Balazs Hegedus, Corey L Pelletier, Jason D Weber, David H Gutmann.   

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant tumor predisposition syndrome in which affected individuals develop astrocytic brain tumors (gliomas). To determine how the NF1 gene product (neurofibromin) regulates astrocyte growth and motility relevant to glioma formation, we have used Nf1-deficient primary murine astrocytes. Nf1(-/-) astrocytes exhibit increased protein translation and cell proliferation, which are mediated by Ras-dependent hyperactivation of the mammalian target of rapamycin (mTOR) protein, a serine/threonine protein kinase that regulates ribosomal biogenesis, protein translation, actin cytoskeleton dynamics, and cell proliferation. In this study, we show that Nf1-deficient astrocytes have fewer actin stress fibers and exhibit increased cell motility compared with wild-type astrocytes, which are rescued by pharmacologic and genetic mTOR inhibition. We further show that mTOR-dependent regulation of actin stress fiber formation, motility, and proliferation requires rapamycin-sensitive activation of the Rac1 GTPase but not elongation factor 4E-binding protein 1/S6 kinase. Nf1(-/-) astrocytes also exhibit increased protein translation and ribosomal biogenesis through increased expression of the nucleophosmin (NPM) nuclear-cytoplasmic shuttling protein. We found that NPM expression in Nf1(-/-) astrocytes was blocked by rapamycin in vitro and in vivo and that expression of a dominant-negative NPM mutant protein in Nf1(-/-) astrocytes rescued actin stress fiber formation and restored cell motility and proliferation to wild-type levels. Together, these data show that neurofibromin regulates actin cytoskeleton dynamics and cell proliferation through a mTOR/Rac1-dependent signaling pathway and identify NPM as a critical mTOR effector mediating these biological properties in Nf1-deficient astrocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510408     DOI: 10.1158/0008-5472.CAN-06-4470

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

2.  The role of Lamin A in cytoskeleton organization in colorectal cancer cells: a proteomic investigation.

Authors:  Clare R Foster; Joanne L Robson; William J Simon; Jeremy Twigg; Derek Cruikshank; Robert G Wilson; Chris J Hutchison
Journal:  Nucleus       Date:  2011-09-01       Impact factor: 4.197

3.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

4.  Bergmann glial ensheathment of dendritic spines regulates synapse number without affecting spine motility.

Authors:  Jocelyn J Lippman Bell; Tamar Lordkipanidze; Natalie Cobb; Anna Dunaevsky
Journal:  Neuron Glia Biol       Date:  2010-11-02

Review 5.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

6.  Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.

Authors:  Thomas J Turbyville; Demirkan B Gürsel; Robert G Tuskan; Jessica C Walrath; Claudia A Lipschultz; Stephen J Lockett; David F Wiemer; John A Beutler; Karlyne M Reilly
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

7.  Bulbispermine: a crinine-type Amaryllidaceae alkaloid exhibiting cytostatic activity toward apoptosis-resistant glioma cells.

Authors:  Giovanni Luchetti; Robert Johnston; Véronique Mathieu; Florence Lefranc; Kathryn Hayden; Anna Andolfi; Delphine Lamoral-Theys; Mary R Reisenauer; Cody Champion; Stephen C Pelly; Willem A L van Otterlo; Igor V Magedov; Robert Kiss; Antonio Evidente; Snezna Rogelj; Alexander Kornienko
Journal:  ChemMedChem       Date:  2012-03-02       Impact factor: 3.466

8.  Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.

Authors:  Xiaodong Zhou; Sung-Hoon Kim; Ling Shen; Hyo-Jung Lee; Changyan Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 10.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.